MVA-BASED VACCINE AGAINST COVID-19 EXPRESSING SARS-COV-2 ANTIGENS

The present invention is directed to a recombinant modified vaccinia virus Ankara (MVA), which carries one or more nucleic acid sequence/s coding for an antigenic protein of SARS-CoV-2 useful for vaccinating against COVID19. The present invention is further directed to a vaccine composition containi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ESTEBAN RODRÍGUEZ, Mariano, GARCÍA ARRIAZA, Juan Francisco
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention is directed to a recombinant modified vaccinia virus Ankara (MVA), which carries one or more nucleic acid sequence/s coding for an antigenic protein of SARS-CoV-2 useful for vaccinating against COVID19. The present invention is further directed to a vaccine composition containing said recombinant MVA as well as to a method for enhancing T cell and humoral immune responses in a mammal against COVID19. La présente invention concerne un virus de la vaccine Ankara modifié (MVA) recombinant, qui porte une ou plusieurs séquences d'acide nucléique codant pour une protéine antigénique du SARS-CoV-2 utiles pour la vaccination contre la COVID19. La présente invention concerne en outre une composition de vaccin contenant ledit MVA recombinant, ainsi qu'un procédé pour améliorer les réponses immunitaires humorales et lymphocytaires chez un mammifère contre la COVID19.